Vir Biotechnology Inc
VIR · NASDAQ
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.
Market Data
Price
$9.88
+0.08 (+0.82%)
Market Cap$1.49B
P/E Ratio—
EPS$—
52W High$10.94
52W Low$4.16
Beta1.76
Data from Finnhub · Updated Mar 11, 2026